(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 October 2014 (02.10.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/160401 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *C07D 417/04* (2006.01)
C07D 405/14 (2006.01) *C07D 417/14* (2006.01)
C07D 413/14 (2006.01) *C07D 471/04* (2006.01)
C07D 403/06 (2006.01) *C07D 487/04* (2006.01)
C07D 403/14 (2006.01) *A61K 31/433* (2006.01)
C07D 409/14 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2014/026498

(22) International Filing Date:
13 March 2014 (13.03.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/780,263 13 March 2013 (13.03.2013) US
61/780,248 13 March 2013 (13.03.2013) US

(71) Applicants: **BOSTON BIOMEDICAL, INC.** [US/US]; 640 Memorial Drive, Cambridge, MA 02139 (US). **DAINIPPON SUMITOMO PHARMA CO.,LTD** [JP/JP]; 6-8 Dosho-machi 2-chome, Chuo-ku, Osaka-shi, Osaka, 541-8524 (JP).

(72) Inventors: **LI, Chiang, J.**; 8 Museum Way, Unit 1606, Cambridge, MA 02141 (US). **LIU, Ji-feng**; 23 Nathaniel Road, Winchester, MA 01890 (US). **LI, Wei**; 19 Black Oak Road, Wayland, MA 01778 (US). **GIBEAU, Amanda**; 110 East Central St, Unit 4, Natick, MA 01760 (US). **ROGOFF, Harry**; 55 Walnut Road, Wrentham, MA 02093 (US). **TSUBOI, Katsunori**; Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 554-0022 (JP). **TAKANASHI, Yosuke**; Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 554-0022 (JP). **TOJO, Shingo**; Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 554-0022 (JP). **KODAMA, Tomohiro**; Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 554-0022 (JP). **KUBOTA, Katsumi**; Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 554-0022 (JP). **KANAI, Toshio**; Dainippon Sumitomo Pharma Co., Ltd., 1-98, Kasugadenaka 3-chome, Konohana-ku, Osaka-shi, Osaka, 554-0022 (JP).

(74) Agents: **ELRIFI, Ivor, R.** et al.; Mintz Levin Cohn Ferris Glovsky And Popeo, P.C., One Financial Center, Boston, MA 02111 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

[Continued on next page]

(54) Title: 3-(ARYL OR HETEROARYL) METHYLENEINDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF CANCER STEM CELL PATHWAY KINASES FOR THE TREATMENT OF CANCER



(I)

(57) Abstract: The invention provides compounds of Formula I as inhibitors of cancer stem cells as well as cancer stem cell pathway kinase and other related kinases, pharmaceutical compositions and uses thereof in the treatment of cancer or a related disorder in a mammal, wherein i.a. R_2 is an optionally substituted heterocycle or optionally substituted aryl; and one of R_4, R_5, $R_6$and R_7 is a substituted heterocycle or substituted aryl.

WO 2014/160401 A1

HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*